bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
Company profile
Ticker
TECH
Exchange
Website
CEO
Charles Kummeth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TECHNE CORP /MN/
SEC CIK
Corporate docs
Subsidiaries
Research and Diagnostic Systems Inc. • Bio-Techne China Co. Ltd • ProteinSimple Ltd. • Novus Biologicals, LLC • Bio-Techne Ltd. • Advanced Cell Diagnostics, Inc. • Exosome Diagnostics, Inc. • Asuragen, Inc. • Cyvek, Inc ...
IRS number
411427402
TECH stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
7 Feb 24
8-K
Bio-techne Releases Second Quarter Fiscal 2024 Results
1 Feb 24
8-K
BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT
8 Jan 24
10-Q
2024 Q1
Quarterly report
7 Nov 23
8-K
Bio-techne Releases First Quarter Fiscal 2024 Results
31 Oct 23
8-K
Bio-techne Appoints Kim Kelderman As Chief Executive Officer
19 Oct 23
ARS
2023 FY
Annual report to shareholders
13 Sep 23
DEFA14A
Additional proxy soliciting materials
13 Sep 23
DEF 14A
Definitive proxy
13 Sep 23
10-K
2023 FY
Annual report
23 Aug 23
Transcripts
TECH
Earnings call transcript
2024 Q2
1 Feb 24
TECH
Earnings call transcript
2024 Q1
31 Oct 23
TECH
Earnings call transcript
2023 Q4
8 Aug 23
TECH
Earnings call transcript
2023 Q3
3 May 23
TECH
Earnings call transcript
2023 Q2
2 Feb 23
TECH
Earnings call transcript
2023 Q1
1 Nov 22
TECH
Earnings call transcript
2022 Q4
7 Aug 22
TECH
Earnings call transcript
2022 Q3
4 May 22
TECH
Earnings call transcript
2022 Q2
1 Feb 22
TECH
Earnings call transcript
2022 Q1
2 Nov 21
Latest ownership filings
4
Shane Bohnen
5 Apr 24
4
Roeland Nusse
11 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
William Geist
5 Feb 24
4
Matthew McManus
5 Feb 24
3
Matthew McManus
5 Feb 24
4
Kim Kelderman
5 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
4
James Hippel
21 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 148.66 mm | 148.66 mm | 148.66 mm | 148.66 mm | 148.66 mm | 148.66 mm |
Cash burn (monthly) | 10.64 mm | 1.38 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 71.03 mm | 9.24 mm | n/a | n/a | n/a | n/a |
Cash remaining | 77.63 mm | 139.43 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 7.3 | 100.8 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
92.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 512 |
Opened positions | 68 |
Closed positions | 58 |
Increased positions | 166 |
Reduced positions | 205 |
13F shares | Current |
---|---|
Total value | 9.88 tn |
Total shares | 145.42 mm |
Total puts | 108.00 k |
Total calls | 249.13 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 18.35 mm | $1.25 tn |
BLK Blackrock | 18.28 mm | $1.24 tn |
STT State Street | 6.22 mm | $423.29 bn |
Bamco | 5.38 mm | $365.94 bn |
Select Equity | 4.88 mm | $331.91 bn |
T. Rowe Price | 3.86 mm | $262.14 bn |
Neuberger Berman | 3.72 mm | $253.50 bn |
Geode Capital Management | 3.62 mm | $245.80 bn |
MS Morgan Stanley | 3.31 mm | $225.03 bn |
Brown Capital Management | 3.16 mm | $214.97 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Shane Bohnen | Common Stock | Payment of exercise | Dispose F | No | No | 67.87 | 747 | 50.70 k | 1,647 |
3 Apr 24 | Shane Bohnen | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,259 | 0.00 | 2,394 |
3 Apr 24 | Shane Bohnen | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,259 | 0.00 | 4,519 |
7 Mar 24 | Roeland Nusse | Common Stock | Sell | Dispose S | No | No | 76.9834 | 10,400 | 800.63 k | 43,097 |
1 Feb 24 | Matthew McManus | Stock Option Common Stock | Grant | Acquire A | No | No | 68.54 | 15,902 | 1.09 mm | 15,902 |
1 Feb 24 | Matthew McManus | Stock Option Common Stock | Grant | Acquire A | No | No | 68.54 | 7,951 | 544.96 k | 7,951 |
1 Feb 24 | Matthew McManus | RSU Common Stock | Grant | Acquire A | No | No | 0 | 13,861 | 0.00 | 13,861 |
1 Feb 24 | Matthew McManus | RSU Common Stock | Grant | Acquire A | No | No | 0 | 2,888 | 0.00 | 2,888 |
1 Feb 24 | William Geist | Common Stock | Payment of exercise | Dispose F | No | No | 68.54 | 1,111 | 76.15 k | 7,759 |
News
Navigating 4 Analyst Ratings For Bio-Techne
18 Apr 24
Deutsche Bank Maintains Buy on Bio-Techne, Lowers Price Target to $82
18 Apr 24
Bio-Techne Surpasses 10K Peer-Reviewed Publications Citing Rnascope Technology
8 Apr 24
Bio-Techne And Nikon Instruments Inc. Announce Partnership To Expand Access To Innovative Spatial Biology Services
28 Mar 24
Bio-Techne: Bolstering Investor Value with Reduced Dividends and Amplified Earnings
26 Feb 24
Press releases
BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY
8 Apr 24
BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE
3 Apr 24
BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS
1 Apr 24
BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES
28 Mar 24
BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA
22 Mar 24